TARGOSPHERE®

TargoSphere® nanocarriers offer all the benefits of standard liposomal technologies, plus the added benefit of specific delivery to various cell populations, including immunocompetent cells. Due to their receptor-targeting functionality, the proprietary nanocarriers can reach intracellular compartments not accessible to other nanocarriers. TargoSphere® can be a solution to enhance efficacy of therapeutic approaches.

TARGOSPHERE

TargoSphere nanocarriers offer all the benefits of standard liposomal technologies, plus the added benefit of specific delivery to various cell populations, including immuno-competent cells. Due to their receptor-targeting functionality, the proprietary nanocarriers can reach intracellular compartments not accessible to other nanocarriers. Therefore, the TargoSphere technology can be a solution to reduce adverse effects and potentially enhance the therapeutic effect in number of diseases.

Rodos Biotarget GmbH is pioneering a range of TargoSphere variants that bind to specific receptors present on different cell types and deliver the intended therapeutic active pharmaceutical ingredients (APIs) such as small molecules, proteins, and nucleic acids inside the cells. For example, some TargoSphere variants bind to C-type lectin receptors (CLRs) that are expressed on professional antigen presenting cells (APCs) that play a role in immune response, hepatocytes, myofibroblasts and other cells. The TargoSphere technology can be aligned to customers’ needs regarding targeting selectivity, payload, delivery route, and release characteristics. This toolbox approach offers a customizable technology to target disease-relevant cells and tissues allowing to conceptualize a wide range of nanomedicines.  

TargoSphere Nanocarrier for targeted drug delivery
TargoSphere – A versatile drug enabling technology
CLR-TargoSphere – A useful tool for immune modulation

Example of use: CLR-TargoSphere

The CLR-TargoSphere variant, for example, is a useful tool to intervene with the biology of CLRs. Distinct infectious agents such as viruses, bacteria and fungi have been shown to subvert the function of CLRs on cell surfaces to escape from anti-infectious immune response and promote infection. These infectious agents use CLRs as attachment receptors through envelope glycoproteins on their surface and facilitate their transmission into susceptible cells and alter signaling cascades responsible for innate and adaptive immune responses to establish infection.   
A multitude of other factors are responsible for dysregulation of numerous signaling pathways in various cells attributed to number of other diseases. For example, dysregulation of signaling cascades in hepatocytes and fibroblast with CLRs contribute to liver diseases, and in APCs, which occur due to the processing of autoantigens and inflammatory proteins, trigger autoimmune response in autoimmune diseases.   
By applying CLR-TargoSphere to anti-infective proteins and small molecules, Rodos Biotarget has so far, developed antiviral and antibacterial nanomedicines proved to have a broad spectrum of potential applications against viruses  (e.g., the Human Immunodeficiency Virus Type 1 and the Influenza A Virus  H1N1 subtype, the Hepatitis C Virus) and bacteria (Mycobacterium tuberculosis) in our studies.  The emerging TargoSphere nanomedicine with small molecules, proteins and nucleic acids from Rodos Biotarget will address a broader spectrum of immunological and non-immunological diseases.
A multitude of other factors are responsible for dysregulation of numerous signaling pathways in various cells attributed to number of other diseases. For example, dysregulation of signaling cascades in hepatocytes and fibroblast with CLRs contribute to liver diseases, and in APCs, which occur due to the processing of autoantigens and inflammatory proteins, trigger autoimmune response in autoimmune diseases.   
By applying CLR-TargoSphere to anti-infective proteins and small molecules, Rodos Biotarget has so far, developed antiviral and antibacterial nanomedicines proved to have a broad spectrum of potential applications against viruses  (e.g., the Human Immunodeficiency Virus Type 1 and the Influenza A Virus  H1N1 subtype, the Hepatitis C Virus) and bacteria (Mycobacterium tuberculosis) in our studies.  The emerging TargoSphere nanomedicine with small molecules, proteins and nucleic acids from Rodos Biotarget will address a broader spectrum of immunological and non-immunological diseases.

Rodos BioTarget GmbH

Medical Park Hannover

Feodor-Lynen-Str. 31
30625 Hannover / Germany

Telefon: +49 (511) 7273 8835
Telefax: +49 (511) 7273 8837

E-Mail: info@biotargeting.eu
www.biotargeting.eu

Potsdam Science Park

Am Mühlenberg 11
14476 Potsdam / Germany

Telefon: +49 (511) 7273 8835
Telefax: +49 (511) 7273 8837

E-Mail: info@biotargeting.eu
www.biotargeting.eu